Nov 23, 2021

New Psychedelic Molecules: What’s in Development?

Welcome aboard! Your submission has been received and you are now a member of the community.
Oops! Something went wrong while submitting the form. Please check the format of your entry.
Subscribe to Excellence

By Cristela Tello Ruiz

November 13, 2021

Growing evidence suggests that psychedelics have tremendous potential to treat mental illness in an effective and lasting way. However, the hallucinogenic effects of these new psychedelic molecules can sometimes complicate treatment. While there’s an argument to be made that the active aspect of a psychedelic trip could be crucial for personal growth, for many users it might also be very uncomfortable.

Researchers are currently investigating ways to retain the beneficial properties of these substances without the hallucinogenic experience. Many companies are actively working on developing new molecules that are derived from psychedelic compounds, such as psilocybin or LSD, that offer all of the therapeutic benefits with a reduction, or at least more controlled action, of the psychoactive effects. If nothing else, the current interest in new psychedelic molecules is leading down fascinating paths in the treatment of pervasive mental health conditions, as well as rare and severe illnesses.

Read the full article here


The work included in this article is based on current events, technical charts, company news releases, and the author’s opinions. It may contain errors, and you shouldn’t make any investment decision based solely on what you read here. This publication contains forward-looking statements, including but not limited to comments regarding predictions and projections. Forward-looking statements address future events and conditions and therefore involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements. This publication is provided for informational and entertainment purposes only and is not a recommendation to buy or sell any security. Always thoroughly do your own due diligence and talk to a licensed investment adviser prior to making any investment decisions. Junior resource and biotechnology companies can easily lose 100% of their value so read company profiles on for important risk disclosures. It’s your money and your responsibility.